Recurrent pneumonia mortality risk in a HIV/AIDS Puerto Rican cohort

Cell Mol Biol (Noisy-le-grand). 2003 Dec;49(8):1199-204.

Abstract

Recurrent pneumonia (RP) within 12 months is one of the AIDS diagnosis criteria. To gain knowledge of RP infection in HIV-infected patients, we studied 145 RP cases detected in a cohort of 2,996 HIV patients in Puerto Rico between Jan. 1992-Dec. 2001. The RP prevalence was 4.8%; 77.2% were males and 62.1% were injecting drug users (IDU). At the time of RP diagnosis, the mean CD4+ T cell count was 93.8 cells/mm3, 59.3% were in antiretroviral treatment, 13% had received the pneumococcal vaccine and 84.8% had another AIDS related condition. Over 37% received two or more antiretroviral medications. The death rate in the first year after the RP diagnosis was 63.4%. A Cox proportional hazard analysis showed that CD4+ T cells <200/mm3 (p<0.05), history of toxoplasmosis (p<0.01), wasting syndrome (p<0.01), esophageal candidiasis (p<0.05) and lower number of antiretroviral medications (p<0.05) increased their mortality risk. The studied patients had a highly compromised immune system and a very low pneumococcal vaccination percent at the time of RP diagnosis. Low CD4+ T cells significantly increased the hazard and mortality risk of the cases studied. Antecedents of antiretroviral therapy in these patients ensure a better outcome with lower mortality. Efforts to increase the vaccination rate should reduce the RP incidence in our HIV-infected population.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Female
  • HIV Infections / complications*
  • HIV Infections / epidemiology
  • HIV Infections / mortality
  • Humans
  • Male
  • Middle Aged
  • Mortality
  • Pneumococcal Vaccines / therapeutic use
  • Pneumonia / etiology*
  • Pneumonia / mortality*
  • Pneumonia / prevention & control
  • Prevalence
  • Puerto Rico / epidemiology
  • Recurrence
  • Risk Factors
  • Substance Abuse, Intravenous / complications

Substances

  • Anti-Retroviral Agents
  • Pneumococcal Vaccines